American Vanguard Corporation

21/08/2024 | Press release | Distributed by Public on 21/08/2024 13:33

American Vanguard Withdraws Dacthal Registration

Product Was Suspended by EPA Based on One Rodent Study


American Vanguard Corporation (NYSE: AVD) today announced that, following its decision in April 2024 to voluntarily stop sales of Dacthal herbicide products, the Company has submitted to the Environmental Protection Agency ("EPA") voluntary cancellation requests for all of its federal registrations of those products. Those registrations are currently the subject of an emergency suspension order that was issued by EPA on August 6, 2024.

In connection with its action, the Company made the following statements.

While the Company continues to question EPA's conclusions in support of the suspension, we believe that the best course of action is to voluntarily cancel registrations of this product. We are working apace with both state and federal authorities to effect product return and to remove Dacthal from channels of distribution. It is the Company's position that product stewardship be international in scope; thus, we will now proceed to voluntarily cancel all international registrations as well.

It is important to note that EPA's findings are based upon the test results of a single, relatively new study that the Company had provided to the agency over two years ago which showed an effect on fetal rodents at certain dose levels. As is typically the case with such studies, the observed effect was extrapolated to indicate a potential effect upon human beings. The suspension order, then, was issued by EPA on the premise of preventing potential harm, rather than in response to an actual, reported harm. The Company had been working with the EPA in good faith for over one year to identify risk mitigation measures that might alleviate concerns and allow continued use of high-benefit use patterns. However, these measures apparently did not give the EPA sufficient certainty at the time. The Company was also discussing with the EPA the potential for completion of additional toxicology and exposure studies that may have alleviated risk concerns, had they been afforded time to proceed. The Company nevertheless thanks EPA for expending time and resources to consider and evaluate the many proposed risk mitigation measures.

CONTACT INFORMATION

Company
American Vanguard Corporation
Anthony Young, Director of Investor Relations
[email protected]
(949) 221-6119

Investor Representative
The Equity Group Inc.
www.theequitygroup.com
Lena Cati
[email protected]
(212) 836-9611